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The onset of Parkinson’s disease (PD) is characterized by focal motor features in one body
part, which are usually correlated with greater dopaminergic depletion in the contralateral
posterior putamen. The role of dopamine (DA) hemispheric differences in the onset and
progression ofmotor symptoms of PD, however, remains undeﬁned. Previous studies have
demonstrated that unilateral manipulations of one nigrostriatal system affect contralateral
DA turnover, indicating a functional and compensatory inter-dependence of the two nigros-
triatal systems. In preliminary data obtained by our group from asymmetric PD patients, a
higher asymmetry index asmeasured by 6-[18F] ﬂuoro-L-dopa (18F-DOPA) positron emission
tomography (PET) was associated with a higher threshold (i.e., greater dopaminergic loss)
for the onset of motor symptoms in the less-affected side. To further elucidate the under-
lying basis for this, we carried out a complementary study in monkeys using PET to assess
and correlate the degree of dopaminergic striatal depletion with motor activity. Control and
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-intoxicated monkeys with symmetri-
cal lesions were characterized behaviorally and with 18F-DOPA PET. In parallel, an acute
lesion was inﬂicted in the nigrostriatal projection unilaterally in one monkey, generating a
30% dopaminergic depletion in the ipsilateral striatum, which was not associated with any
noticeable parkinsonian feature or deﬁcit. The monkey remained asymptomatic for several
months. Subsequently, thismonkey received systemicMPTP, followingwhichmotor behav-
ior and PET were repeatedly evaluated during progression of parkinsonian signs.The brains
of all monkeys were processed using immunohistochemical methods. Our results suggest
that the onset of motor signs is related to and inﬂuenced by the dopaminergic status of
the less-affected, contralateral striatum. Although this work is still preliminary, the study
agrees with our general hypothesis of hemispheric inter-dependence in the compensation
of striatal DA deﬁcit in PD.
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INTRODUCTION
Parkinson’s disease (PD) is a neurodegenerative disorder char-
acterized mainly by neuronal cell loss predominantly affecting
the nigrostriatal dopaminergic pathway (Dickson et al., 2009).
However, disease progression is also associated with neuronal
loss in the serotonergic, cholinergic, and noradrenergic neuro-
transmitter systems and with widespread synuclein pathology
(Halliday et al., 2008).
The loss of dopaminergic striatal innervation in PD pro-
gresses over a period of years before classical motor fea-
tures arise (Nandhagopal et al., 2009). Accordingly, very powerful
compensatory mechanisms must therefore be activated in order
to maintain motor activity within normal clinical limits during
this pre-symptomatic stage, now recognized to last for a sig-
niﬁcant period of time (mean 7 years). Indeed, initial motor
manifestations typically appear when about 70–80% of striatal
nerve terminals and 50–60% of substantia nigra pars compacta
(SNc) neurons have been lost (Bernheimer et al., 1973; Fearn-
ley and Lees, 1990, 1991). Remarkably, such a large reduction
is associated with very mild clinical manifestations conﬁned to
a body segment, i.e., slowness of one hand, tremor of the foot,
shoulder rigidity, etc., which is paralleled by unequal striatal inner-
vation and asymmetric dopaminergic neuronal loss (Fearnley and
Lees, 1991).
One essential feature of PD at onset is the focal and asym-
metrical distribution of motor signs, the cause of which remains
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elusive (Djaldetti et al., 2006). Animal models generally produce
generalized bilateral deﬁcits (Beal, 2010), which preclude analysis
of this essential early asymmetric characteristic. Indeed, the basal
ganglia model and its variants that have been developed since the
mid-1980s have been unable to address the role and functional
signiﬁcance of inter-hemispheric connectivity. Thus, basal gan-
glia pathophysiology has been discussed and elaborated without
including bilateral, inter-hemispheric connectivity, and possible
physiological inﬂuences. Accordingly, the role of dopamine (DA)
hemispheric differences in the onset and progression of motor
features of PD remains by and large undeﬁned (Djaldetti et al.,
2006). Previous studies in animal models provoking acute or
chronic unilateral lesion of the dopaminergic nigrostriatal sys-
tem have shown a reciprocal interaction between the intact and
DA-depleted striatum (Nieoullon et al., 1977; Andersson et al.,
1980; Van Camp et al., 2010). Some previous reports studying the
effects of unilateral and bilateral partial lesions of the nigrostriatal
system in 6-hydroxydopamine (6-OHDA) rats suggested an inter-
dependent regulation of the twonigrostriatal systems,which could
provide some compensatory support for the lesioned hemisphere
(Rodriguez et al., 1990; Castellano et al., 1993; Roedter et al., 2001).
In earlier 6-[18F] ﬂuoro-L-dopa (18F-DOPA) positron emission
tomography (PET) studies onPDpatients, we obtained datawhich
strongly suggest that complete or partial indemnity of striatal DA
in one hemisphere increases signiﬁcantly the capacity of the pri-
marily damaged striatum to compensate for DA depletion (Juri
et al., 2009). Herewe compared the features of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys of different
symptom severitywith those observed in onemonkeywith a surgi-
cal lesion of the nigrostriatal system followed up with progressive
systemic MPTP administration to induce an asymmetrical parkin-
sonism. This represents a preliminary case-study regarding an
asymmetrical model where the onset of motor features and striatal
DA depletion has been monitored in vivo by using 18F-DOPA PET.
We realize the limitations of an (n = 1) observation. Nevertheless,
this is a model which mimics more closely the onset and evolution
of motor features in PD patients, and it is therefore potentially
very useful to ascertain newer therapeutic agents.
MATERIALS AND METHODS
ANIMALS
Seventeen monkeys (Macaca fascicularis; 4.7 ± 1.1 years old) from
RC Hartelust (Tilburg, The Netherlands), weighing 3.6 ± 1.02 kg,
were included in this study. Animals were housed in an ani-
mal room under standard conditions of air exchange (16 l/min),
humidity (50%), and light/dark cycles (8 a.m. to 8 p.m.) and were
fed fresh fruit and commercial pellets, with free access to water. All
procedures were performed according to the European Council
Directive 86/609/EEC and in accordance with the Society for Neu-
roscience Policy on the Use of Animals in Neuroscience Research.
The University of Navarra Ethics Committee for Animal Testing
and state authorities approved the experimental design.
Bilateral symmetric parkinsonism
Parkinsonism was induced as previously reported (Blesa et al.,
2010) by systemic administration (i.v.) of MPTP using a low-dose
regimen (0.5 mg/kg every 2 weeks) to obtain partial, slowly pro-
gressive and bilateral degeneration of the nigrostriatal dopamin-
ergic system. In order to classify the motor status, a validated
motor score (Kurlan scale; Kurlan et al., 1991) was used. Four
animals were included in each group and classiﬁed as: (1) Con-
trol, normal, intact monkeys (n = 4); (2) Asymptomatic, animals
that received MPTP but never showed any evidence of motor
impairment (n = 4); (3) Initial Parkinsonian, this group con-
sisted of four monkeys that developed mild motor features
for several weeks. Subsequently, without further intoxication
they showed minimal residual parkinsonian features or com-
plete motor recovery. Accordingly, they were considered to be
at the threshold between the asymptomatic and symptomatic
stages; (4) Stable Parkinsonian, were those monkeys that exhibited
parkinsonian features after MPTP and remained affected there-
after (n = 4). Each animal had to remain stable for at least
1 month in the corresponding motor state to be classiﬁed in a
given group.
To generate the model, motor behavior was analyzed weekly
after MPTP injection. Inter-subject sensitivity to MPTP leads
to variable outcomes during the initial intoxication period (ﬁrst
two doses). A monkey that was free of motor manifestations
after the second injection was considered to be Asymptomatic
and received no further MPTP. All other monkeys developed
parkinsonian features after the initial MPTP doses. Four of these
animals with initial motor symptoms were left to improve until
they exhibited only minimal or no motor (Initial Parkinsonian)
features without further intoxication, while others continued to
receive MPTP until a stable parkinsonian state was obtained
(Stable Parkinsonian). The latter showed bilateral and symmet-
ric motor deﬁcits which persisted unchanged until the end of
the study.
Bilateral asymmetric parkinsonism (case-study monkey)
One monkey (M. fascicularis; 4 years old, weight 2.5 kg) was
used in this preliminary study. First, a unilateral lesion of
the right nigrostriatal pathway was made. Following anesthesia
(ketamine/midazolam) the monkey was ﬁxed to a stereotactic
device and a trepanus was performed following the right sub-
thalamic nucleus (STN) coordinates (6 mm posterior and 4 mm
lateral to anterior commissure and 27.5 mm ventral to the dura).
The STN was localized by neuronal extracellular recordings.
A mechanical lesion was made ventromedial to STN without
affecting it.
Subsequently, several months after establishing the initial
focal lesion which interrupted the nigrostriatal projection uni-
laterally, the same monkey received systemic administration
(i.v.) of MPTP using a low-dose regimen of 0.25 mg/kg every
2 weeks on four occasions which resulted in early and mild
unilateral parkinsonian features contralateral to the previously
lesioned side. Then, 0.5 mg/kg was given every 2 weeks until
the development of bilateral motor features consistent with sta-
ble parkinsonism. This allowed the severity and evolution of
motor features to be separated and for each hemibody to be
designated according to the Primary Affected Side (the right
side of the body) or Secondary Affected Side (the left side of
the body).
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MOTOR BEHAVIOR
Peanuts test
This manual motor task test measured the time taken for the mon-
key to reach out and retrieve four peanuts that had been placed
in front of it. The test was performed with the monkey comfort-
ably seated in a cage speciﬁcally prepared for this purpose, with a
methacrylate front panel and two symmetrical holes with a diam-
eter of 5 cm. Each hole corresponded to the positioning of each of
the hands. Peanuts were placed within circles (2 cm in diameter) in
a tray directly in line with the panel holes. The examiner recorded
the time taken for the monkey to perform the test ﬁve times with
each hand alternately.
PET STUDIES
Positron emission tomography studies were conducted using the
radioligand 18F-DOPA in a dedicated small animal Philips Mosaic
tomograph (Cleveland, OH, USA). The radiotracer was intra-
venously injected through the saphenous vein simultaneously to
the beginning of a list mode study. To block peripheral decar-
boxylation of 18F-DOPA, 50 mg of carbidopa was given orally 1 h
prior to the scans and anesthesia. Anesthesia was initially induced
by intramuscular injections of ketamine (10 mg/kg) and midazo-
lam (1 mg/kg) to allow preparation and handling of the monkeys.
Anesthesia was maintained during the scans with a mixture of
ketamine (5 mg/kg) and midazolam (0.5 mg/kg).
Studies were conducted using baseline conditions and after sta-
bilization in the different motor states in the bilaterally lesioned
animals. Regarding the case-study monkey with unilateral lesion
of the nigrostriatal pathway and subsequent MPTP intoxication,
the assessments were conducted following the mechanical lesion,
and then 2 weeks after the second MPTP dose when the monkey
was still asymptomatic, after the onset of unilateral parkinson-
ism, and when bilateral parkinsonian features had developed. A
stabilization period was also allowed after the onset of unilateral
and bilateral parkinsonism before conducting the studies. PET
data acquisitions and analyses were performed using the standard
protocol described previously by our group (Collantes et al., 2009;
Blesa et al., 2010).
HISTOLOGICAL ANALYSIS
Animals were perfused with saline, followed by 4% paraformalde-
hyde in phosphate buffer (PB, 0.1 M, pH 7.4) and a series of
PB sucrose solutions (5–20%). Brains were removed from the
skull, cut into 40 μm thick coronal sections and stored for
immunohistochemical procedures (Cavada et al., 1995). Tyro-
sine hydroxylase (TH) positive cells in the mesencephalon were
counted by stereological analysis. Dopaminergic innervation was
studied by immunostaining of TH in the striatum. All analyses
were performed on the right hemisphere.
IMMUNOHISTOCHEMICAL PROCEDURES
Immunoreactivity for TH was localized using the protocol out-
lined in Sanchez-Gonzalez et al. (2005). Brieﬂy, sectionswere incu-
bated with mouse anti-TH antibody (1/1000 dilution: MAB5280
Chemicon International, Temecula, CA, USA), followed by a sec-
ondary biotinylated antibody (1/400 dilution: AP160B; 1:400;
Chemicon International, Temecula, CA, USA). Visualization was
carried out using Avidin/Biotin complex (ABC) Vectastain Elite
(Vector Labs, Burlingame,CA,USA) anddiaminobenzidine (DAB;
Sigma).
QUANTIFICATION METHODS
Estimates of the number of TH-immunoreactive(-ir) neuronal
bodies in the mesencephalon were quantiﬁed according to stere-
ological principles. Eight coronal sections, regularly spaced at
intervals of 1200 μm, from the caudal edges of the mammil-
lary bodies rostrally to the decussation of the superior cerebellar
peduncle caudally, were analyzed for each animal. The stere-
ology system consisted of a Zeiss Axioskop optical microscope
(Oberkochen, Germany) equipped with a digital camera (Axio-
Cam HRc, Zeiss, Germany) and StereoInvestigator software
(version 8.0, MicroBrightField, Williston, VT, USA). The camera
settings were maintained throughout the duration of the experi-
ment. We traced arbitrary landmarks based on external references
with the StereoInvestigator software to delineate the SNc (A9) and
ventral tegmental area (A10) in each region of interest.
The relative density of TH-ir ﬁbers in the caudate and puta-
men was quantiﬁed by measuring the optical density (OD) of
immunostainingusing Image J (1.41o,NIH,USA) software. A total
of seven rostro-caudal sections for each monkey – three anterior
and four posterior to the anatomical references – regularly spaced
at intervals of 2400 μm were examined.
STATISTICS
All statistics were performedwith SPSS software (version 16.0 soft-
ware for Windows; SPSS Inc., Chicago, IL, USA). Two-sided p
values of less than 0.05 and 0.01 were considered signiﬁcant.
Differences in continuous andnormally distributed variables of
18F-DOPA Ki, numbers of TH-ir cells, and optical densities were
analyzed using two-way repeated measures analyses of variance
(ANOVA), followed by the Bonferroni post hoc test. Normality
was checked by the Kolmogorov–Smirnov test.
RESULTS
MOTOR BEHAVIOR
Monkeys that received systemic MPTP could be categorized as
Asymptomatic, Initial Parkinsonian, and Stable Parkinsonian at
the time of analysis (9 weeks after last MPTP dose). The group
of monkeys labeled as Initial Parkinsonian developed moder-
ate parkinsonism (Kurlan scale score of ∼5) after initial MPTP
doses and were subsequently left to stabilize (Kurlan scale ∼2).
Stable Parkinsonian monkeys developed relatively severe bilateral
motor deﬁcits during the intoxication phase (Kurlan scale scores
of ∼17), but some recovery took place during the stabilization
period, so that by the end of the experiment they showedmoderate
parkinsonian features (Kurlan scale score of ∼11).
The case-study monkey showed no motor abnormality ini-
tially, as evidenced by the results of the motor scale and peanuts
test, despite relatively signiﬁcant dopaminergic depletion of the
right striatum (see below). Subsequently, MPTP administration
induced progressive bradykinesia, which manifested on the left
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FIGURE 1 | Motor behavior. Evolution of hand bradykinesia using the
peanuts test in the case-study monkey with asymmetric involvement of
the nigrostriatal dopaminergic system. The left hand (contralateral to the
Primary Affected Side) exhibits a progressive increase in time taken to
complete the test in parallel with increased 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP) total dose, while the right hand shows
modest involvement.
side as clearly shown by the motor scale and the asymmetric loss
of motor ability, contralateral to the Primary Affected Side in the
peanuts test (Figure 1). As the effect of MPTP progressed, parkin-
sonian features became more severe and generalized. This monkey
FIGURE 2 | (A) Representative 6-[18F] ﬂuoro-L-dopa (18F-DOPA) positron
emission tomography (PET) brain images of the asymmetrically
affected (case-study) monkey in coronal and transversal orientation at
baseline, after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment
(∼Initial Parkinsonian), and after the ﬁnal MPTP administration (∼Stable
Parkinsonian). (B) Comparison of 18F-DOPA uptake in control and
MPTP-treated monkeys (n = 16; white line), and dopaminergic uptake of the
Primary Affected Side (yellow line) and Secondary Affected Side (red line) in
the case-study monkey with asymmetric dopamine depletion. In this
last-mentioned monkey with the asymmetric lesion, a constant
asymmetry between both striata is observed after the unilateral lesion,
which remained more or less stable after MPTP administration. Note
that the observed depletion at the beginning of parkinsonism in the
Primary Affected Side is greater than expected based on the general
model. Data represent mean ± SEM. Symbols indicate signiﬁcant
differences between groups. *p < 0.01 compared with control; #p < 0.01
compared with asymptomatic; &p < 0.05 compared with recovered
group.
thus exhibited bilateral, albeit asymmetrical, parkinsonism by the
end of the intoxication period.
PET STUDY
The 18F-DOPA PET showed a linear reduction of uptake in the
monkey groups receiving parenteral MPTP (Figure 2). Such a
pattern of uptake reduction correlated very signiﬁcantly with the
Kurlan motor score (p = 0.00; R = 0.77), SNc cell loss (p = 0.00;
R = 0.93), and decline of striatal TH immunolabeling (p = 0.00;
R = 0.91).
In the monkey with the unilateral lesion, 18F-DOPA PET
uptake was reduced in the Primary Affected Side by 30% with
respect to the contralateral side and continued to decrease bilat-
erally once MPTP was given. Importantly, the initial asymmetry
in 18F-DOPA uptake was maintained during MPTP intoxication
until the last stage, when the monkey had developed bilateral
motor features (Figure 2). For this one monkey, it was notice-
able that the magnitude of dopaminergic depletion associated
with the onset of motor manifestations in the lesioned side (Pri-
mary Affected Side) was much higher than that observed in the
model of symmetric parkinsonisms induced by systemic MPTP
administration.
HISTOLOGY
Tyrosine hydroxylase innervation of the striatum
For the case-study monkey, TH immunoreactivity reduction was,
as expected, greater in the Primary Affected Side (Figure 3).
In monkeys with MPTP-induced bilateral deﬁcit, a progressive
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FIGURE 3 | Coronal brain sections showing tyrosine hydroxylase
(TH) immunolabeling in the left and right hemispheres of the
case-study monkey with a unilateral dopaminergic lesion. Images
show the left (A) and right (B) hemispheres at the level of the anterior
commissure. Note that theTH immunolabeling is much heavier in the left
caudate (Cd) and putamen (Put) than on the right side. (C) Illustration of
the track of the electrode (black arrows) that caused the lesion in the
nigrostriatal pathway (white arrowhead). Note the asymmetry in TH
immunolabeling between the left and right bodies of the caudate nucleus
(Cd). (D)TH immunolabeling is weaker on the right versus left substantia
nigra pars compacta (SNc). Also note that the subthalamic nucleus
appears intact.
reduction in the level of immunoreactivity for TH was observed
in the striatum (Figure 4A), which correlated with the severity
of parkinsonism for the different groups. The magnitude of the
reduction in the case-study monkey TH immunoreactivity was
close to that (i.e., greatest loss) for the Stable Parkinsonian group
(Figure 4A).
Dopaminergic cells in the mesencephalon
For monkeys receiving MPTP parenterally, the number of TH-ir
neurons in A9 declined in parallel with the increased severity
of motor deﬁcits (Figure 4B). The minimal cell loss was a 37%
reduction with respect to controls in the Asymptomatic group;
this is in comparison to the Stable Parkinsonian group which
showed a 75% reduction. For the case-study monkey, cell counts
of TH-ir neuronal cell bodies in the mesencephalon showed bilat-
eral loss of these neurons in the SNc (A9), which was greater
in the Primary Affected Side (Figure 4B) than in the Secondary
Affected Side. Moreover, the values ﬁt well with the degree of
motor deﬁcit, so that the most severe parkinsonian features in
the Primary Affected Side corresponded with a lower cell count
than the less severe Secondary Affected Side. Importantly, cell loss
in the SNc of the Primary Affected Side was greater even than
that of monkeys with Stable Parkinsonism. Cell loss in A10 (ven-
tral tegmental area) was similar to that observed in monkeys
with parkinsonism induced by systemic MPTP administration
(Figure 4C).
FIGURE 4 | Tyrosine hydroxylase (TH) immunostaining in the striatum
and mesencephalon. (A) Line graph showing progressive reduction in
the optical density (OD) quantitative analysis of TH immunostaining in the
striatum. Line graphs showing the effect of 1-methyl-4-phenyl-1,2,3,
6-tetrahydropyridine (MPTP) administration on the number of TH-positive
cells remaining in the substantia nigra pars compacta (A9) (B), and ventral
tegmental area (A10) (C) of control and MPTP-treated monkeys. For
comparison, the number of TH-positive cells remaining in each region and
the OD in the striatum of the Primary Affected Side (blue circle) and
Secondary Affected Side (green circle) of the asymmetric monkey is
shown. Data represent mean ± SEM. Symbols indicate signiﬁcant
differences between groups. *p < 0.01 compared with control; #p < 0.01
compared with asymptomatic.
DISCUSSION
The manner by which the brain compensates for progressive
striatal DA depletion over the course of many years before
clinical motor features of PD are manifested is yet to be eluci-
dated. The main recognized compensatory mechanisms include
increased dopaminergic pre-synaptic turnover, down-regulation
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of pre-synaptic dopaminergic auto-receptors and DA trans-
porter, andup-regulationof post-synaptic dopaminergic receptors
(Hornykiewicz and Kish, 1987; Zigmond et al., 1989; Zigmond,
1997; Brotchie and Fitzer-Attas, 2009). Undoubtedly, the more
classic and reputedly compensatory mechanism of striatal deple-
tion in PD consists of an increased DA striatal turnover, as
established in the 6-OHDA-lesioned rat model (Zigmond et al.,
1990) and in human PD patients (Hornykiewicz, 1975; Zigmond
et al., 1990; Piﬂ and Hornykiewicz, 2006). More recently, some
studies have challenged the fundamental role attributed to stri-
atal DA turnover in compensating for PD. Thus, substantia nigra
(SN) ﬁring was not found to be signiﬁcantly increased in the uni-
lateral 6-OHDA rat model (Rodriguez and Gonzalez-Hernandez,
1999), and the changes in striatal DA turnover in the MPTP mon-
key model were observed too late in the evolution of the process to
account for the pre-symptomatic period (Bezard et al., 2001). This
led to the suggestion that other compensatorymechanisms beyond
the striatum may be more relevant or important in the early phase
of PD (Bezard et al., 2003). These may include increased gluta-
matergic and serotonergic striatal input (Boulet et al., 2008) and
modulation of basal ganglia output circuits and beyond (Obeso
et al., 2004; Tang et al., 2011).
A possible role of the inter-hemispheric inﬂuence of basal gan-
glia function and compensation of the dopaminergic deﬁcit has
been suggested but has received little attention. To this extent,
crossed afferents to the striatum from the contralateral SN and
ventral tegmental area were observed in the rat, which persisted
after corpus callosotomy (Fass and Butcher, 1981). Nieoullon et al.
(1977) showed in cats that infusion of DA in the SNc (resulting
in a decreased DA concentration in the striatum) was associated
with an increase in the liberation of DA in the contralateral stria-
tum and the opposite effect when the DA infusion was stopped
(Nieoullon et al., 1977). In rats with an ibotenic acid-induced stri-
atal lesion, Narang et al. (1993) demonstrated increased striatal
D2 receptor mRNA expression contralaterally. Neurophysiologic
changes have also been demonstrated contralaterally to unilateral
lesions; for example, a decrease in the rate of neuronal discharge
in the contralateral STN (Perier et al., 2000) or an increase in
the ﬁring rate of contralateral SN GABAergic neurons (Gonzalez-
Hernandez et al., 2004). With speciﬁc relevance to our current
approach, a study comparing the effect of unilateral versus bilat-
eral striatal 6-OHDA lesions in rats showed a marked aggravation
of locomotor and exploratory behavior and the use of the fore-
limbs, suggesting a functional compensatory inter-dependence of
the two nigrostriatal systems (Roedter et al., 2001). Finally, we have
obtained preliminary ﬁndings in PD patients suggesting that the
absence of clinically evident signs in early unilateral PD is related
not onlywith the dopaminergic depletion of the less-affected stria-
tumbut also to the degree of putamenKi asymmetry between sides
(Juri et al., 2009).
We report here for the ﬁrst time a direct comparison between
symmetrical and asymmetrical dopaminergic depletion in the
MPTP monkey model. We readily acknowledge that the results are
very preliminary as only one monkey with an asymmetrical lesion
has been studied and some un-controlled variables could poten-
tially undermine these preliminary results. For instance, the lesion
could have impinged upon the STN or its efferent connections to
the globus pallidus pars interna, which would have had an anti-
parkinsonian effect. However we believe that such a possibility is
unlikely anatomically as well as in terms of the putative impact on
motor behavior. Thus, the focal lesion was medio-ventral to the
STN and the efferent ﬁbers projecting from the motor STN to the
motor globus pallidus pars interna and externa are dorso-lateral,
and therefore, quite remote from the lesion site. These motor
ﬁbers arising from the dorso-lateral STN are well recognized to be
responsible for conveying excessive glutamatergic activity, which
gives rise to the parkinsonian state. Thus, we have no doubt the
motor STN was completely spared in this monkey. In the sym-
metrical monkeys there was a very powerful correlation between
motor behavior and degree of dopaminergic lesion as evaluated
by PET in vivo and post-mortem. The case-study monkey with
asymmetric lesion did not ﬁt into such a general pattern, showing
a higher reduction in 18F-DOPA uptake in the PET studies and
greater SNc cell loss than expected for the degree of motor deﬁcit.
In other words, the asymmetric monkey tolerated a more severe
dopaminergic lesion before becoming fully parkinsonian.
These ﬁndings support the hypothesis that the contralateral
dopaminergic activity of the less-affected hemisphere plays a
role in compensating for dopaminergic depletion of the most
affected hemisphere in PD. To our knowledge this is the ﬁrst con-
certed attempt to analyze using PET the role of inter-hemispheric
asymmetry in DA depletion.
Asymmetry in the onset of the motor manifestations is a char-
acteristic feature of PD. The cause of this asymmetry is not known
(Djaldetti et al., 2006), but it could reﬂect a different vulnerability
of the SNc to the factor(s) involved in the genesis of the disor-
der. Data from PD patients have suggested that those with higher
asymmetry could evolve slower than those with a more symmet-
rical motor involvement (Poewe, 2006), particularly when tremor
is the predominant motor manifestation (Djaldetti et al., 2006).
CONCLUSION
The data presented here indicate that asymmetry of dopaminergic
depletion is probably involved in the clinical manifestations of the
primarily affected body side in PD patients. The precise mecha-
nisms of such inter-hemispheric inﬂuence and inter-dependence
are not well understood and warrant further investigation. Our
ﬁndings open a new experimental approach to study PD and may
be highly relevant when considering the early treatment of PD
in general, and the application of neuroprotective therapies in
particular.
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